延长高剂量甲泼尼龙对比常规地塞米松治疗COVID-19肺炎的随机对照试验(MEDEAS)
多中心开放标签随机对照试验纳入677例需氧疗或无创呼吸支持的COVID-19肺炎成人患者,比较甲泼尼龙80mg/d连续输注8天后缓慢减量 vs 地塞米松6mg/d最多10天。28天死亡率无显著差异(10.4% vs 12.1%,p=0.49),甲泼尼龙组存活者住院时间更长但CRP改善更明显。
要点
- 延长高剂量甲泼尼龙未降低28天死亡率,不优于常规地塞米松。
- 两组无机械通气天数、ICU转诊率、气管切开率均无显著差异。
- 甲泼尼龙组存活者住院时间更长,但CRP改善更明显。
核心结论
- 延长高剂量甲泼尼龙对比常规地塞米松未降低COVID-19肺炎28天死亡率。
研究设计与样本
- 多中心开放标签随机对照试验,纳入677例需氧疗或无创呼吸支持的COVID-19肺炎成人患者。
- 甲泼尼龙组337例接受80mg/d连续静脉输注8天后缓慢减量,地塞米松组340例接受6mg/d最多10天。
主要发现
- 28天死亡率甲泼尼龙组35例(10.4%)vs 地塞米松组41例(12.1%),p=0.49。
- 无机械通气天数中位数(IQR)23(14)vs 24(16)天,p=0.49。
- ICU转诊41例(12.2%)vs 45例(13.2%),p=0.68;气管切开8例(2.4%)vs 9例(2.6%),p=0.82。
- 存活者住院时间中位数(IQR)15(11)vs 14(11)天,p=0.005。
- 甲泼尼龙组第7天和第14天CRP水平改善,但PaO2/FiO2比值无改善。
临床怎么用
- 对于需要氧疗或无创呼吸支持的COVID-19肺炎成人患者,延长高剂量甲泼尼龙不优于常规地塞米松方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dysregulated systemic inflammation is the primary driver of mortality in severe coronavirus disease 2019 (COVID-19) pneumonia. Current guidelines favour a 7-10-day course of any glucocorticoid equivalent to dexamethasone 6 mg daily. A comparative randomised controlled trial (RCT) with a higher dose and a longer duration of intervention was lacking. METHODS: We conducted a multicentre, open-label RCT to investigate methylprednisolone 80 mg as a continuous daily infusion for 8 days followed by slow tapering versus dexamethasone 6 mg once daily for up to 10 days in adult patients with COVID-19 pneumonia requiring oxygen or noninvasive respiratory support. The primary outcome was reduction in 28-day mortality. Secondary outcomes were mechanical ventilation-free days at 28 days, need for intensive care unit (ICU) referral, length of hospitalisation, need for tracheostomy, and changes in C-reactive protein (CRP) levels, arterial oxygen tension/inspiratory oxygen fraction (P aO2 /F IO2 ) ratio and World Health Organization Clinical Progression Scale at days 3, 7 and 14. RESULTS: 677 randomised patients were included. Findings are reported as methylprednisolone (n=337) versus dexamethasone (n=340). By day 28, there were no significant differences in mortality (35 (10.4%) versus 41 (12.1%); p=0.49) nor in median mechanical ventilation-free days (median (interquartile range (IQR)) 23 (14) versus 24 (16) days; p=0.49). ICU referral was necessary in 41 (12.2%) versus 45 (13.2%) (p=0.68) and tracheostomy in 8 (2.4%) versus 9 (2.6%) (p=0.82). Survivors in the methylprednisolone group required a longer median (IQR) hospitalisation (15 (11) versus 14 (11) days; p=0.005) and experienced an improvement in CRP levels, but not in P aO2 /F IO2 ratio, at days 7 and 14. There were no differences in disease progression at the prespecified time-points. CONCLUSION: Prolonged, higher dose methylprednisolone did not reduce mortality at 28 days compared with conventional dexamethasone in COVID-19 pneumonia.
引用
- Salton F, Confalonieri P, Centanni S, et al. Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). Eur Respir J. 2023. PMID: 36356972. doi:10.1183/13993003.01514-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。